JP2024543259A - ＳＡＲＳ－ＣｏＶ－２感染を治療する方法 - Google Patents

ＳＡＲＳ－ＣｏＶ－２感染を治療する方法 Download PDF

Info

Publication number
JP2024543259A
JP2024543259A JP2024531268A JP2024531268A JP2024543259A JP 2024543259 A JP2024543259 A JP 2024543259A JP 2024531268 A JP2024531268 A JP 2024531268A JP 2024531268 A JP2024531268 A JP 2024531268A JP 2024543259 A JP2024543259 A JP 2024543259A
Authority
JP
Japan
Prior art keywords
cov
sars
infection
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531268A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023092180A5 (https=
JP2024543259A5 (https=
Inventor
ミラー，ミシェル
ディニーン エワート，ゲイリー
Original Assignee
バイオトロン リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021903789A external-priority patent/AU2021903789A0/en
Application filed by バイオトロン リミティッド filed Critical バイオトロン リミティッド
Publication of JP2024543259A publication Critical patent/JP2024543259A/ja
Publication of JPWO2023092180A5 publication Critical patent/JPWO2023092180A5/ja
Publication of JP2024543259A5 publication Critical patent/JP2024543259A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024531268A 2021-11-24 2022-11-24 ＳＡＲＳ－ＣｏＶ－２感染を治療する方法 Pending JP2024543259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021903789A AU2021903789A0 (en) 2021-11-24 Methods of treating sars-cov-2 infection
AU2021903789 2021-11-24
PCT/AU2022/051405 WO2023092180A1 (en) 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection

Publications (3)

Publication Number Publication Date
JP2024543259A true JP2024543259A (ja) 2024-11-20
JPWO2023092180A5 JPWO2023092180A5 (https=) 2025-11-25
JP2024543259A5 JP2024543259A5 (https=) 2025-11-25

Family

ID=86538440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531268A Pending JP2024543259A (ja) 2021-11-24 2022-11-24 ＳＡＲＳ－ＣｏＶ－２感染を治療する方法

Country Status (8)

Country Link
US (1) US20250009713A1 (https=)
EP (1) EP4436576A4 (https=)
JP (1) JP2024543259A (https=)
KR (1) KR20240110039A (https=)
CN (1) CN118574614A (https=)
AU (1) AU2022399231A1 (https=)
CA (1) CA3238183A1 (https=)
WO (1) WO2023092180A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596107A (en) * 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
ES2563477T3 (es) * 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
SG11201907034PA (en) * 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
US20220409587A1 (en) * 2019-11-26 2022-12-29 Biotron Limited Methods of treating hiv-1 infection
US11660307B2 (en) * 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2021207049A1 (en) * 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs

Also Published As

Publication number Publication date
CN118574614A (zh) 2024-08-30
WO2023092180A1 (en) 2023-06-01
CA3238183A1 (en) 2023-06-01
EP4436576A4 (en) 2025-09-17
KR20240110039A (ko) 2024-07-12
EP4436576A1 (en) 2024-10-02
US20250009713A1 (en) 2025-01-09
AU2022399231A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR102607599B1 (ko) 인플루엔자의 치료 방법
US12167994B2 (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN114786659A (zh) 用于治疗汉坦病毒感染的mek抑制剂
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CN116098917A (zh) 核苷类化合物在治疗冠状病毒感染性疾病中的用途
CN111407754A (zh) 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用
JP2024543259A (ja) ＳＡＲＳ－ＣｏＶ－２感染を治療する方法
JP7293225B2 (ja) 組合せ製品を用いるｒｓｖの処置
EP4613275A1 (en) Pharmaceutical use of nucleoside compound
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
WO2025257398A1 (en) Dicarboxylic acids and esters thereof for use in the treatment of a viral lung infection
CA3052503C (en) Methods of treating influenza
TW201731515A (zh) 用於治療茲卡病毒感染之方法及組合物
CN117838698A (zh) 奥拉替尼在制备治疗流感病毒感染的药物中的应用
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
HK40017310B (en) Methods of treating influenza
HK40017310A (en) Methods of treating influenza

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114